New hair loss drug for women enters final testing phase
NCT ID NCT07303322
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase 3 trial tests whether an oral solution called N1087 can help women with female pattern hair loss regrow hair. About 372 women aged 18 to 60 will receive either N1087 or a placebo daily for 24 weeks. The study measures changes in hair density and thickness using scalp photos.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- N1087 (oral solution)
- What this could lead to
- If it works, this could offer a new daily treatment option to help women with thinning hair regrow thicker hair.
- What could go wrong
- This is an early Phase 3 trial, so results are not yet known. The drug may not work better than placebo, and side effects are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FEMALE PATTERN HAIR LOSS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.